Pathological stage I endometrial carcinoma: the role for adjuvant radiotherapy.
BACKGROUND
In order to assess the efficacy of adjuvant radiotherapy in the treatment of pathological stage I endometrial carcinoma, we performed a retrospective analysis of 158 patients with this diagnosis who after surgery were either treated with radiation therapy or only followed from January 1980 through December 1987.


METHODS
Patients were divided into two prognostic categories, high and low risk, on the basis of three known predictors of survival: histology, differentiation, and depth of myometrial invasion. All patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy but only the high risk group received radiotherapy as well.


RESULTS
After a median follow up time of 59 months the survival rates of the two groups were similar. The 5-year disease-free survival of the surgery alone group was 92% compared to 89% for the postoperative radiotherapy group. Side effects of treatment were minimal.


CONCLUSIONS
Postoperative radiation therapy for high risk pathological stage I endometrial carcinoma is an effective adjuvant therapy and confers an excellent prognosis.
Barhum
M
M
Northern Israel Oncology Center, Rambam Medical Center, Haifa.
Stein
M
M
Ronsenblatt
E
E
Dale
J
J
Kuten
A
A
D002277:Carcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome